retatrutide phase 2 trial weight loss 🚨 is out: 24.2% mean and a quarter lost >30%! Women lost more weight than men. #ADA2023 was like drinking from a fire hose for emerging anti-obesity Effects of once-weekly subcutaneous retatrutide

It is estimated that total diabetes-related healthcare expenditure in China has escalated from $51 billion in $2015 to $109 billion in 2019 (Zhang, 2022)

One is Virta Health, which advertises its nutrition-focused weight management program as a proven approach for deprescribing GLP-1s when clinically appropriate. A Virta-funded study assessed 154 people with Type 2 diabetes who stopped using GLP-1 medications but continued following Virtas program, concluding that their weight did not significantly increase after a year

We encourage individuals to ask questions, verify sources, and seek advice from qualified healthcare professionals before using any weight-loss medication

Low GLP activity is often linked with obesity, insulin resistance, and type 2 diabetes

N., Svendsen, B., Dragsted, L

To maintain these benefits, however, you may need to continue taking GLP-1 receptor agonists indefinitely